

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-166. (Canceled).

167. (Currently Amended) A silicon ~~implant~~biocompatible product comprising a drug and ~~hydrophobic resorbable~~semiconductor mesoporous silicon obtained by heating with an oxidizing agent, having a pore size between 20 Å and 500 Å, the drug being at least partly located in the pores of the porous silicon.

168.-171. (Canceled).

172. (Currently Amended) A silicon implant according to claim 167 wherein the ~~resorbable~~ mesoporous silicon has a structure such that it is tissue compatible.

173.-176. (Canceled).

177. (New) A method of delivering a drug to a human or animal subject comprising the steps (a) administering the biocompatible silicon product comprising an organic drug and semiconductor mesoporous silicon obtained by heating with an oxidizing agent, having a pore size between 20 Å and 500 Å, the drug being at least partly located in the pores of the porous silicon, and (b) allowing the drug to escape from the pores of the porous silicon.